Please use this identifier to cite or link to this item: http://bura.brunel.ac.uk/handle/2438/19231
Full metadata record
DC FieldValueLanguage
dc.contributor.authorGuo, D-
dc.contributor.authorHua, X-
dc.contributor.authorJiang, K-
dc.date.accessioned2019-10-04T11:24:18Z-
dc.date.available2017-06-21-
dc.date.available2019-10-04T11:24:18Z-
dc.date.issued2017-06-21-
dc.identifier.citationInternational Journal of Industrial Organization, 2017, 54 pp. 37 - 64en_US
dc.identifier.issn0167-7187-
dc.identifier.issnhttp://dx.doi.org/10.1016/j.ijindorg.2017.06.007-
dc.identifier.urihttp://bura.brunel.ac.uk/handle/2438/19231-
dc.format.extent37 - 64-
dc.language.isoenen_US
dc.publisherElsevieren_US
dc.subjectAgency,en_US
dc.subjectEntry Threat,en_US
dc.subjectStrategic Right,en_US
dc.subjectTermination JEL Classifications: D86,en_US
dc.subjectL22,en_US
dc.subjectL24,en_US
dc.subjectO30en_US
dc.titleAgency and strategic contracts: Theory and evidence from R&D agreements in the pharmaceutical industryen_US
dc.typeArticleen_US
dc.identifier.doihttp://dx.doi.org/10.1016/j.ijindorg.2017.06.007-
dc.relation.isPartOfInternational Journal of Industrial Organization-
pubs.publication-statusPublished-
pubs.volume54-
Appears in Collections:Brunel Business School Research Papers

Files in This Item:
File Description SizeFormat 
FullText.pdf450 kBAdobe PDFView/Open


Items in BURA are protected by copyright, with all rights reserved, unless otherwise indicated.